Chen, Chu-Huang

1

BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.

Follow this format for each person. DO NOT EXCEED FOUR PAGES.

NAME Chen, Chu-Huang eRA COMMONS USER NAME

chchen1

POSITION TITLE

Director Vascular and Medicinal Research

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)

INSTITUTION AND LOCATION DEGREE (if applicable) YEAR(s) FIELD OF STUDY

Kaohsiung Medical College, Kaohsiung, Taiwan M.D. 1978 Medicine Chang-Gung Memorial Hospital, Taipei, Taiwan Resident 1978-1981 Pathology Texas Tech University, Lubbock, Texas Ph.D. 1986 Physiology Maryland General Hospital & Univ. of Maryland Resident 1986-1989 Internal Medicine Baylor College of Medicine, Houston, Texas Fellow 1989-1992 Cardiology

A. Positions and Honors Professional Experience 1992-1993 Postdoctoral Associate, Section of Atherosclerosis/Medicine, Baylor College of Medicine 1993-1994 Instructor of Medicine, Baylor College of Medicine, Houston, Texas 1994-2004 Assistant Professor of Medicine, Baylor College of Medicine, Houston, Texas 2004-present Associate Professor of Medicine, Baylor College of Medicine, Houston, Texas 2006-present Clinical Director, Behavioral Medicine Research Center, Department of Medicine, Baylor College of Medicine, Houston, Texas 2009-present Professor and Director, Vascular and Medicinal Research, Wafic Said Molecular Cardiology Research Laboratories, Texas Heart Institute at St. Luke’s Hospital, Houston, Texas 2010-present Visiting Professor and Director of L5 Research Center, China Medical University, Taichung, Taiwan 2012-present Visiting Professor and Director of Center for Lipid Biosciences, Kaohsiung Medical University, Kaohsiung, Taiwan 2013-present Chairman, Research Advisory Committee, New York Heart Research Foundation, New York

Honors and Awards 1) Tar box Fellowship, Texas Tech University, 1983–1986 2) The Methodist Hospital Foundation Award, 1993–1994 3) The Virginia and Ernest Cockrell Jar Award, 1994 4) Zeneca Pharmaceuticals Research Award, 1993–1995 5) AHA, Texas Affiliate, Grant-In-Aid, 1995–1997 6) Texas Medical Center/NASA Cooperative Research Grant, 1995–1996 7) AHA, National, Scientist Development Award, 1997–2000 8) The Atorvastatin Research Award, 1999–2000 9) American Diabetes Association Research Award, 2000–2003 10) Pfizer Independent Medical Grant, 2002–2003 11) American Diabetes Association Research Award, 2004–2006 12) Pfizer Independent Medical Grant, 2004–2005

Chen, Chu-Huang

2

13) Philip Morris Research Award, 2005–2008 14) AHA grant reviewer, Western Review Consortium, 2004–2008; 2011–present 15) Associate Editor, Journal of Alzheimer’s Disease, 2011–2012 16) 12th Generation Chen Style Tai Chi Selected Disciple, 2013 – permanent

Honors as a Mentor 1) Postdoctoral Fellow, Jeffrey P. Walterscheid, Ph.D., AHA Fellowship, 2006 2) Postdoctoral Fellow, Daming Tang, M.D., Ph.D., NIH Training Grant, 2007

Memberships in Professional Societies 1) American Diabetes Association 2) AHA, Atherosclerosis Council 3) International Atherosclerosis Society 4) American Association for the Advancement of Science 5) The Angiogenesis Society B. Publications Selected peer-review publications (in reversed order) *corresponding author 1. Chang PY, Chen YJ, Chang FH, Lu J, Huang WH, Yang TC, Lee YT, Chang SF, Lu SC, Chen CH*.

Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: A novel cytoprotective role of aspirin in acute myocardial infarction. Cardiovasc Res. 2013 Mar 20. [Epub ahead of print]. PMID: 23519265

2. Unick JL, Beavers D, Bond DS, Clark JM, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, Wagenknecht LE, Wing RR; Look AHEAD Research Group. The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med. 2013;126:236-242, 242.e1-2. PMID: 23410564 (Chen CH: Look AHEAD Co-Investigator).

3. Tsai MH, Chang CL, Yu YS, Lin TY, Chong CP, Yang JY, Lin YS, Su MY, Shu TY, Lu J, Chen CH*, Liu MY. Chemical analysis of C-reactive protein synthesized by human aortic endothelial cells under oxidative stress. Anal Chem. 2012;84:9646-9654. PMID: 23046186

4. Rejeski WJ, Ip EH, Bertoni AG, Bray GA, Evans G, Gregg EW, Zhang Q; Look AHEAD Research Group. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med. 2012;366:1209-1217. PMID: 22455415 (Chen CH: Look AHEAD Co-Investigator).

5. Chen CH*, Lu J, Chen SH, Huang RY, Yilmaz HR, Dong J, Elayda MA, Dixon RAF, Yang CY. Effects of electronegative VLDL on endothelium damage in metabolic syndrome. Diabetes Care. 2012;35:648-653. PMID: 22279032

6. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, Pownall HJ, Johnson KC, Safford MM, Kitabchi AE, Pi-Sunyer FX, Wing RR, Bertoni AG; for the Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of Type 2 diabetes. JAMA. 2012;308:2489-2496. PMID: 23288372 (Chen CH: Look AHEAD Co-Investigator).

7. Lee AS, Wang GJ, Chan HC, Chen FY, Chang CM, Yang CY, Lee YT, Chang KC, Chen CH*. Electronegative low-density lipoprotein induces cardiomyocyte apoptosis indirectly through endothelial cell–released chemokines. Apoptosis. 2012;17:1009-18. PMID: 22562555

8. Chen CY, Hsu HC, Lee AS, Tang D, Chow LP, Yang CY, Chen H, Lee YT, Chen CH*. The most negatively charged low-density lipoprotein L5 induces stress pathways in vascular endothelial cells. J Vasc Res. 2012;49:329-341. PMID: 22627396

9. Wang GJ, Chang CT, Yang CY. Chen CH* Negatively charged L5 as a naturally occurring atherogenic low-density lipoprotein. BioMedicine. 2012;2:147-154.

10. Chang PY, Lee CM, Hsu HC, Lin HJ, Chien KL, Chen MF, Chen CH, Lee YT, Yang CY. Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population:

Chen, Chu-Huang

3

The Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan. Lipids Health Dis. 2012;11:162. [Epub ahead of print]. PMID: 23173569

11. Chang CT, Liao HY, Chang CM, Chen CY, Chen CJ, Chen CH, Yang CY. Oxidized ApoC1 on MALDI-TOF and glycated-ApoA1 band on gradient gel as potential diagnostic tools for atherosclerotic vascular disease Clinica Chimica Acta. 2012 Oct 15. pii: S0009-8981(12)00484-6. doi: 10.1016/j.cca.2012.10.017. [Epub ahead of print]. PMID: 23078847

12. Belalcazar LM, Lang W, Haffner SM, Hoogeveen RC, Pi-Sunyer FX, Schwenke DC, Balasubramanyam A, Tracy RP, Kriska AP, Ballantyne CM; Look AHEAD Research Group. Adiponectin and the mediation of HDL-cholesterol change with improved lifestyle: the Look AHEAD Study. J Lipid Res. 2012;53:2726-2733. PMID: 22956782 (Chen CH: Look AHEAD Co-Investigator).

13. Wang YC, Lo PH, Chang SS, Lin JJ, Wang HJ, Chang CP, Hsieh LC, Chen YP, Chen WK, Chen CH, Chang KC, Hung JS. Reduced door-to-balloon times in acute ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Int J Clin Pract. 2012;66:69-76. PMID: 22171906

14. Chang KC, Huang CL, Liang HY, Chang SS, Wang YC, Liang WM, Lane HY, Chen CH, Huang, SK. Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. J Cardiovasc Electrophysiol. 2012;23:527-33. PMID: 22136144

15. Ribisl PM, Gaussoin SA, Lang W, Bahnson J, Connelly SA, Horton ES, Jakicic JM, Killean T, Kitzman DW, Knowler WC, Stewart KJ; Look AHEAD Research Group. Lifestyle intervention improves heart rate recovery from exercise in adults with type 2 diabetes: results from the Look AHEAD study. J Obes. 2012;2012:309196. PMID: 23227314 (Chen CH: Look AHEAD Co-Investigator).

16. McCaffery JM, Papandonatos GD, Peter I, Huggins GS, Raynor HA, Delahanty LM, Cheskin LJ, Balasubramanyam A, Wagenknecht LE, Wing RR; Genetic Subgroup of Look AHEAD; Look AHEAD Research Group. Obesity susceptibility loci and dietary intake in the Look AHEAD Trial. Am J Clin Nutr. 2012;95:1477-1486. PMID: 22513296 (Chen CH: Look AHEAD Co-Investigator).

17. Wang IK, Lai HC, Yu CJ, Liang CC, Chang CT, Kuo HL, Yang YF, Lin CC, Lin HH, Liu YL, Chang YC, Wu YY, Chen CH, Li CY, Chuang FR, Huang CC, Lin CH, Lin HC. Real-time PCR Analysis of intestinal microbiota in peritoneal dialysis patients. Appl Environ Microb. 2012;78:1107-1112. PMID: 22179250

18. Peter I, McCaffery JM, Kelley-Hedgepeth A, Hakonarson H, Reis S, Wagenknecht LE, Kopin AS, Huggins GS; Genetics Subgroup of the Look AHEAD Study. Association of type 2 diabetes susceptibility loci with one-year weight loss in the look AHEAD clinical trial. Obesity (Nature Publishing Group). 2012;20:1675-1682. PMID: 22307069 (Chen CH: Look AHEAD Co-Investigator).

19. Faulconbridge LF, Wadden TA, Rubin RR, Wing RR, Walkup MP, Fabricatore AN, Coday M, Van Dorsten B, Mount DL, Ewing LJ; Look AHEAD Research Group. One-year changes in symptoms of depression and weight in overweight/obese individuals with type 2 diabetes in the Look AHEAD study. Obesity (Nature Publishing Group). 2012;20:783-793. PMID: 22016099 (Chen CH: Look AHEAD Co-Investigator).

20. Schwartz AV, Johnson KC, Kahn SE, Shepherd JA, Nevitt MC, Peter AL, Walkup MP, Hodges A, Williams CC, Bray GA, Look AHEAD Research Group. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J Bone Miner Res. 2012:27:619-627. PMID: 22354851 (Chen CH: Look AHEAD Co-Investigator).

21. Brancati FL, Evans M, Furberg CD, Geller N, Haffner S, Kahn SE, Kaufmann PG, Lewis CE, Nathan DM, Pitt B, Safford MM; Look AHEAD Study Group. Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials. 2012;9:113-124. PMID: 22334468 (Chen CH: Look AHEAD Co-Investigator).

22. Wong SL, Chang HS, Wang GJ, Chiang MY, Huang HY, Chen CH, Tsai SC, Lin CH, Chen LS. 2011, Secondary metabolites from the root of Neolitsea daibuensis and their antiinflammatory activity. J Nat Prod. 2011;74:2489-96. PMID: 22148193

23. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, Wing RR; Look AHEAD Research Group. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2

Chen, Chu-Huang

4

diabetes: results from the Look AHEAD trial. Diabetes Care. 2011;34:2152-2157. PMID: 21836103 (Chen CH: Look AHEAD Co-Investigator).

24. Ke LY, Engler DA, Lu J, Matsunami RK, Chan HC, Wang GJ, Yang CY, Chang JG, Chen CH*. Chemical composition–oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein. Pure Appl Chem. 2011;83:1731–1740. doi:10.1351/PAC-CON-10-12-07

25. Chen HH, Chen CY, Chow LP, Chen CH, Lee YT, Smith CV, Yang CY. Iron-catalyzed oxidation of Trp residues in low-density lipoprotein. Biol Chem. 2011;392:859-867. PMID: 21848505.

26. Huang YT, Chang HS, Wang GJ, Cheng MJ, Chen CH, Yang YJ, Chen IS. Anti-inflammatory endiandric acid analogues from the roots of Beilschmiedia tsangii. J Nat Prod. 2011;74:1875-1880. PMID: 21846089

27. Intensive lifestyle intervention improves physical function among obese adults with knee pain: findings from the Look AHEAD trial. Foy CG, Lewis CE, Hairston KG, Miller GD, Lang W, Jakicic JM, Rejeski WJ, Ribisl PM, Walkup MP, Wagenknecht LE; Look AHEAD Research Group. Obesity (Nature Publishing Group). 2011;19:83-93. PMID: 20559303 (Chen CH: Look AHEAD Co-Investigator).

28. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Look AHEAD Research Group, Wing RR. Arch Intern Med. 2010;170:1566-75. PMID: 20876408 (Chen CH: Look AHEAD Co-Investigator).

29. Chang PY, Lu SC, Chen CH*. S-Adenosylhomocysteine: A better marker of the development of Alzheimer's disease than homocysteine? J Alzheimers Dis. 2010;21:65-66. PMID: 20413857

30. Yang SS, Wang GJ, Cheng KF, Chen CH, Ju YM, Tsau YJ, Lee TH. Bioactive γ-lactones from the fermented broth of Neosartorya sp. Planta Med. 2010;76:1701-1705. PMID:20446242

31. Chang PY, Lu SC, Lee YT, Chen CH*. Comment on: Song et al. (2009) Effect of homocysteine-lowering treatment with folic acid and B vitamins on risk of type 2 diabetes in women: A randomized, controlled trial. Diabetes 58:1921-1928. Diabetes. 2010;59(3):e1. PMID: 20190132

32. Wang GJ, Lin YL, Chen CH, Wu XC, Liao JF, Ren J. Cellular calcium regulatory machinery of vasorelaxation elicited by petasin. Clin Exp Pharmacol Physiol. 2010;37:309–315.

33. Chen CH*, Dixon RAF, Ke LY, Willerson JT. Vascular progenitor cells in diabetes mellitus: Roles of Wnt signaling and negatively charged LDL. Circ Res. 2009;104:1038-1040. PMID:19423862

34. Lu J, Yang JH, Burns AR, Chen HH, Tang D, Walterscheid JP, Suzuki S, Yang CY, Sawamura T, Chen CH*. Mediation of electronegative LDL signaling by LOX-1: A possible mechanism of endothelial apoptosis. Circ Res. 2009;104:619-627. PMID: 19150883

35. One-year weight losses in the Look AHEAD study: factors associated with success. Wadden TA, West DS, Neiberg RH, Wing RR, Ryan DH, Johnson KC, Foreyt JP, Hill JO, Trence DL, Vitolins MZ; Look AHEAD Research Group. Obesity (Silver Spring). 2009;17:713-22 PMID: 19180071 (Chen CH: Co-Investigator).

36. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Williamson DA, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K; Look AHEAD Research Group. Arch Intern Med. 2009;169:163-71. PMID: 19171813 (Chen CH: Co-Investigator).

37. Describing patterns of weight changes using principal components analysis: results from the Action for Health in Diabetes (Look AHEAD) research group. Espeland MA, Bray GA, Neiberg R, Rejeski WJ, Knowler WC, Lang W, Cheskin LJ, Williamson D, Lewis CB, Wing R; Look Ahead Study Group. Ann Epidemiol. 2009;19:701-10. PMID: 19628410 (Chen CH: Co-Investigator).

38. Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH Chang SF, Liao WS, Chen CH, Lee YT. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res. 2008;102:933-941. PMID: 18309099

39. Lu J, Jiang W, Yang JH, Chang PY, Walterscheid JP, Chen HH, Marcelli M, Tang D, Lee YT, Liao WSL, Yang CY, Chen CH*. Electronegative LDL impairs vascular endothelial cell integrity in diabetes by disrupting FGF2 autoregulation. Diabetes. 2008;57:158-166. PMID: 17959932

40. Tang D, Lu J, Walterscheid JP, Chen HH, Engler DA, Sawamura T, Chang PY, Safi HJ, Yang CY, Chen CH*. Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res. 2008;49:33-47. PMID: 17909223

Chen, Chu-Huang

5

41. Yang CH, Chen HH, Huang MT, Raya JL, Yang JH, Chen CH, Gaubatz JW, Pownall HJ, Taylor AA, Ballantyne CM, Jenniskens FA, Smith CV.

Pro-apoptotic low-density lipoprotein subfractions in type II

diabetes atherosclerosis. Atherosclerosis. 2007;193:283-91. 42. Cheng J, Cui R, Chen CH, Du J. Oxidized low-density lipoprotein stimulates p53-dependent activation of

proapoptotic Bax leading to apoptosis of differentiated endothelial progenitor cells. Endocrinology. 2007;485:2085-2094. PMID: 17289842

43. Chen CH*, Walterscheid JP. Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis. Circ Res. 2006;99:787-789. PMID: 17038645

44. Chen CH*. Platelet-activating factor acetylhydrolase: is it good or bad for you? Curr Opin Lipidol. 2004;15:337-341. PMID: 15166791

45. Chen CH*, Poucher SM, Lu J, Henry PD. Fibroblast growth factor 2: From laboratory evidence to clinical application. Curr Vasc Pharmacol. 2004;2:33-43 (figure used for cover page). PMID:15320831

46. Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, Chen CH, Liau CS, Lee YT. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res. 2004;45:2116-2122.

47. Chen CH*, Jiang T, Yang JH, Jiang W, Lu J, Marathe GK, Pownall HJ, Ballantyne CM, McIntyre TM, Henry PD, Yang CY. Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription. Circulation. 2003;107:2102-2108. PMID: 12695302

48. Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, Pownall HJ, Taylor AA, Smith CV. Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Arterioscler Thromb Vasc Biol. 2003;23:1083–1090. PMID: 12689919

49. Chang PY, Luo S, Jiang T, Lee YT, Lu SC, Henry PD, Chen CH*. Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids. Circulation. 2001;104:588-593. PMID: 11479258

50. Chen CH*, Jiang W, Via D, Luo S, Li TZ, Lee YT, Henry PD. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation. 2000;101:171-177. PMID: 10637205

51. Chen CH*, Volding D. Medicinal foods: cross cultural perspectives. In Food As A Drug, edited by Poston WSC. 2000. P. 49–64.

52. Chen CH*, Volding D. Medicinal foods: cross cultural perspectives. Drugs and Society. 1999;15:49-64. 53. Bucay M, Nguy J, Barrios R, Chen CH, Henry PD. Impaired adaptive vascular growth in

hypercholesterolemic rabbit. Atherosclerosis. 1998;139:243-251. 54. Chen CH*, Cartwright J Jar, Li Z, Luo S, Nguyen HH, Gotto AM Jar, Henry PD. Inhibitory effects of

hypercholesterolemia and oxidized LDL on angiogenesis-like endothelial growth in rabbit aortic explants: essential role of basic fibroblast growth factor. Arterioslcer Thromb Vasc Biol. 1997;17:1303-1312.

55. Chen CH*, Henry PD. Atherosclerosis as a microvascular disease: impaired angiogenesis mediated by suppressed basic fibroblast growth factor expression. Proc Assoc Am Physicians. 1997;109:351-361.

56. Chen CH*, Nguyen HH, Weilbaecher D, Luo S, Gotto AM Jar, Henry PD. Basic fibroblast growth factor reverses atherosclerotic impairment of human coronary angiogenesis-like responses in vitro. Atherosclerosis. 1995;116:261-268.

57. Henry PD, Cabello OA, Chen CH. Hypercholesterolemia and endothelial dysfunction. Curr Opin Lipidol. 1995;6:190-195.

58. Chen CH*, Williams J, Lutherer LO. 1994. Cerebellar lesions alter autonomic responses to transient isovolemic changes in arterial pressure. Clin Auton Res. 1994;4:263-272.

59. Henry PD, Chen CH. Inflammatory mechanism of atheroma formation: influence of fluid mechanics and lipid-derived inflammatory mediators. Am J Hypertens. 1993;6(suppl):328-334.

Chen, Chu-Huang

6

60. Chen CH, O'Leary EL, Janssen HF, Lutherer LO. 1985. Changes in ambient temperature alter the blood pressure response to endotoxin and the effectiveness of naloxone. Circ Shock. 1985;16:185-193.

61. Schoenfeld AD, Lox CD, Chen CH, Lutherer LO. Pain threshold changes induced by acute exposure to ambient temperature. Peptides. 1985;6 (suppl 1):19-22.

62. Lutherer LO, Smith AL, Chen CH, O'Leary EL, Lutherer BC. The effect of angiotensin and vasopressin blockade separately and in combination with cerebellectomy on recovery from hemorrhagic hypotension. Circ Shock. 1983;10:329-340.

63. Chen L, Chen CH. Cardiac myxomas: a report of two cases. Modern Medicine in Asia. 1980;16(12), December.

64. Chu CS, Wang YC, Walton B, Yilmaz HR, Huang RY, Sawamura T, Lu LS, Chen CH*, Lu J. Electronegative low-density lipoprotein increases endothelial expression of C-reactive protein through LOX-1 receptor. PLoS One. 2012 (in revision).

65. Chang KC, Lee AS, Chen WY, Chen FY, Chang SS, Pan CC, Chan HC, Lee CY, Chang CT, Su MJ, Chen CH*. Mechanisms of cardiac diastolic dysfunction in a model of cardiorenal syndrome. PLos Medicine. Blood. 2013 (soon to be submitted).

66. Chan HC, Ke LY, Chu CS, Lee AS, Shen MY, Hsu JF, Cruz MA, Cheng KH, Chan HC, Lai WT, Sawamura T, Sheu SH, Yen JH, Chen CH*. Highly electronegative LDL is elevated in patients with acute myocardial infarction and triggers platelet activation and aggregation. Blood. 2012 (soon to be submitted).

67. Wang YC, Chang KC, Chang SS, Lo PH, Chu CS, Lu J, Hsu JF, Ke LY, Sawamura T, Lee YT, Burns AR, Chen CH*. Expression of the highly electronegative LDL receptor LOX-1 is increased in thrombi of STEMI patients. Eur Heart J. 2013 (in preparation).

68. Hsieh JY, Huang Max, Chang CT, Chang CM, Chen CY, Shen MY, Liao HY, Wang GJ, Chen CH, Chen CJ*, Yang CY*. Biochemical and functional characterization of electrical charge-defined subfractions of high-density lipoprotein in normal adult subjects. J Lipid Res. 2013 (in preparation).

69. Wang YC, Lu LS, Dong JW, Lu J, Lee AS, Chen ZP, Chen SH, Dou H, Kuzan TY, Chang KC, Dixon RAF, Chen CH*. The DNA damage response mediates endothelial cell senescence induced by electronegative LDL. Nature. 2012 (in preparation).

70. Shen MY, Chen FY, Lee AS, Ke LY, Sheu JR, Dixon RAF, Hsu CY, Chen CH*. Novel miR-145 decoy attenuates synergistic platelet activation by amyloid beta and electronegative LDL. Cell. 2013 (in preparation).

71. Shen MY, Hsu MJ, Hsu LC, Hsiao G, Lin CH, Chen CH, Sheu JR, Hsu CY. Targeted mitochondrial DNA binding facilitates NF-B activities in anucleate platelets. Circulation. 2012 (in preparation).

Most recent abstract presentations on related subjects at national meetings (since 2000 only) 1. Hsu JF, Chou TC, Hsieh JY, Lu J, Chen SH, Shayani S, Chen CH*. A novel total lipoprotein

electronegativity index for predicting cardiometabolic risk. To be presented at the American Diabetes Association 73rd Scientific Sessions in Chicago, Illinois, June 21-25, 2013.

2. Shen MY, Sheu JR, Chen FY, Dixon RAF, Chen CH*. Electronegative LDL and beta-amyloid synergistically induce platelet activation that can be inhibited by novel microRNA-145 and NF-B decoys. Presented at the American Heart Association-International Stroke Conference in Honolulu, Hawaii, February 6–8, 2013.

3. Chan HC, Ke LY, Chu CS, Lee AS, Shen MY, Cruz MAC, Chan HC, Cheng KH, Lai WT, Yen JH, Sawamura T, Sheu SHS, Chen CH*. Highly Electronegative LDL is Elevated in Patients With Acute Myocardial Infarction and Triggers Platelet Activation and Aggregation. Circulation 2012;126:A9753. Presented at the American Heart Association Scientific Sessions in Los Angeles, CA, November 3–7, 2012.

4. Wang YC, Lu LS, Dong JW, Lu J, Lee AS, Chen SH, Dou H, Kuzan TY, Chang KC, Dixon RA, Chen CH*. The DNA Damage Response Mediates Endothelial Cell Senescence Induced by Electronegative LDL. Circulation 2012;126:A16796. Presented at the American Heart Association Scientific Sessions in Los Angeles, CA, November 3–7, 2012.

Chen, Chu-Huang

7

5. Lee AS, Chen FY, Chang SS, Pan CC, Chan HC, Chang CT, Su MJ, Chen CH*, Chang KC. Mechanisms of Cardiac Diastolic Dysfunction in a Model of Cardiorenal Syndrome. Circulation 2012;126:A12664. Presented at the American Heart Association Scientific Sessions in Los Angeles, CA, November 3–7, 2012.

6. Chang KC, Wang YC, Chang SS, Lo PH, Lu J, Sawamura T, Lee YT, Burns AR, Chen CH*. Expression of the Highly Electronegative LDL Receptor LOX-1 is Increased in Thrombi of STEMI Patients. Circulation 2012;126:A13127. Presented at the American Heart Association Scientific Sessions in Los Angeles, CA, November 3–7, 2012.

7. Wang YC, Lu J, Chen SH, Dong JW, Huang RY, Dixon RAF, Elayda MA, Chen CH*. Electronegative low-density lipoprotein is increased early in cardiometabolic derangement. Published for the American Diabetes Association 72nd Scientific Sessions in Philadelphia, Pennsylvania, June 8-12, 2012.

8. Dong JW, Yilmaz HR, Lu J, Lu LS, Chen SH, Wang YC, Dixon RAF, Chen CH*. Mitochondrial damage by electronegative low-density lipoprotein in metabolic syndrome. Published for the American Diabetes Association 72nd Scientific Sessions in Philadelphia, Pennsylvania, June 8-12, 2012.

9. Chen CH*, Lu J, Dean J, Huang RY, Wang YC, Elayda MA, Dong JW, Chen SH, Dixon RAF. Mechanistic implication of electronegative low-density lipoprotein surge in acute myocardial infarction. J Am Coll Cardiol. 2012;59:E539. Presented at the 61st American College of Cardiology Scientific Sessions in Chicago, IL, March 24–27, 2012.

10. Lu J, Chu CS, Wang YC, Dong JW, Chen SH, Huang RY, Chen CH*. Electronegative low-density lipoprotein increases endothelial expression of C-reactive protein through LOX-1 receptor. J Am Coll Cardiol. 2012;59:E1472. Presented at the 61st American College of Cardiology Scientific Sessions in Chicago, IL, March 24–27, 2012.

11. Lee AS, Wang GJ, Chan HC, Chang KC, Chen FY, Chang CM, Yang CY, Chen CH*. Electronegative low-density lipoprotein induces cardiomyocyte apoptosis through a chemokine-cytokine crosstalk mechanism. J Am Coll Cardiol. 2012;59:E1000. Presented at the 61st American College of Cardiology Scientific Sessions in Chicago, IL, March 24–27, 2012.

12. Chang PY, Chen YJ, Yang TC, Lu SC, Chen CH*. Low-dose aspirin prevents coronary endothelial injury by oxidized-LDL through the Akt-FGF2 prosurvival pathway. J Am Coll Cardiol. 2012;59:E1726. Presented at the 61st American College of Cardiology Scientific Sessions in Chicago, IL, March 24–27, 2012.

13. Ma Y, Lu J, Cheng N, Wu G, Abbasi S, Cheng J, Chen CH, Xi Y. L5 induces cardiomyocytes damage and reduction of cardiac ATP-sensitive K+ Channels. J Am Coll Cardiol. 2012;59:E1055. Presented at the 61st American College of Cardiology Scientific Sessions in Chicago, IL, March 24–27, 2012.

14. Chen CH*, Lu J, Engler DA, Ke LY, Yilmaz HR, Dixon RAF, Chen SH, Yang CY. Biologic Significance of Charge-Based Heterogeneity in Diabetic VLDL Subfractions. Diabetes. 2011;60(Suppl 1):A157. Presented at the American Diabetes Association 71st Scientific Sessions in San Diego, California, June 24-28, 2011.

15. Cheng N, Lu J, Sun J, Wu G, Abbasi S, Zhang J, Cheng J, Chen CH, Xi Y. Most negatively charged subfraction (l5) of plasma ldl prolongs action potential duration of rat cardiomyocytes via LOX-1 receptors. J Am Coll Cardiol. 2011;57:E58. Presented at the 60th American College of Cardiology Scientific Sessions in New Orleans, LA, April 2–5, 2011.

16. Dixon RAF, Lu J, Chen CH. Negatively charged LDL subfraction contributes to both atherosclerosis and hypertension in type 2 diabetes. 3rd World Congress on Controversies in Diabetes, Obesity and Hypertension. Prague, Czech Republic. May 13-16, 2010.

17. Chen CH*, Lu J, Wang GJ, Dixon RAF, Yang CY, Willerson JT. Mechanistic basis of L5 as a novel treatment target for coronary artery disease. 8th International Congress on Coronary Artery Disease. Prague, Czech Republic. October 11–14, 2009.

18. Chang PY, Lee JK, Chen YJ, Lu SC, Lee YT, Chang KC, Pai PY, Chen CH. Identification of an electronegative LDL as potential novel biomarker for acute coronary syndrome. European Society of Cardiology Congress. Barcelona, Spain. August 29–September 2, 2009.

Chen, Chu-Huang

8

19. Tang D, Burns AR, Lu J, Chen HH, Wu H, Morrisett JL, Sawamura T, Yang CY, Chen CH*. Electronegative LDL disrupts mitochondrial homeostasis: a novel mechanism for cigarette smoking-associated endothelial dysfunction. FASEB J. 2008 22:471.12. Presented at the FASEB 2008 meeting, San Diego, CA, April 5–9, 2008.

20. Tang D, Chen HH, Lu J, Engler DA, Sawamura T, Pownall HJ, Yang CY, Chen CH*. Chronic smoking-yielded electronegative LDL induces MEK/ERK mediated metalloproteinase activation in human endothelial progenitor cells. J Am Coll Cardiol. 2008;51(suppl A):A278. Presented at the American College of Cardiology 2008 Scientific Sessions, Chicago, IL, March 29–April, 2008.

21. Tang D, Lu J, Walterscheid JP, Chen HH, Yang JH, Engler DA, Sawamura T, Marcelli M, Yang CY, Chen CH*. Electronegative LDL in smoking subjects inhibits endothelial progenitor cell differentiation by impairing Akt phosphorylation via the LOX-1 receptor. Arterioscler Thromb Vasc Biol. 2007; Presented at the ATVB Annual Conference April 19-21, 2007 Chicago, IL.

22. Lu J, Walterscheid JP, Chen HH, Yang CY, Poucher SM, Chen CH*. Diabetic LDL subfraction induces smooth muscle cell proliferation by enhancing endothelial release of endothelin-1. Diabetes. 2006;55 (suppl 1):A160. Presented at the American Diabetes Association 66th Scientific Sessions in Washington DC. June 9–13, 2006.

23. Lu J, Chen HH, Yang CY, Walterscheid JP, Pownall HJ, Morrisett JD, Chen CH*. C4 Platelet-activating factor mimics electronegative LDL circulating in patients with metabolic syndrome in inducing endothelial cell apoptosis. Diabetes. 2005;54(suppl 1):A193. Presented at the American Diabetes Association 65th Scientific Sessions in San Diego, CA, June 10–14, 2005.

24. Lu J, Yang JH, Chen HH, Yang CY, Henry PD, Walterscheid JP, Morrisett JD, Sawamura T, Chen CH*. Effective attenuation of electronegative LDL-induced endothelial cell apoptosis by gene silencing of the lectin-like receptor for oxidized LDL. J Am Coll Cardiol. 2005. Presented at the 54th American College of Cardiology Scientific Sessions in Orlando, FL, March 6–9, 2005.

25. Tai MH, Kuo SM, Huang MT, Yang JH, Chen HH, Lu J, Sawamura T, Chen CH, Yang CY. Activation of caspase 13 by diabetic electronegative LDL through lectin-like oxidized LDL receptor-1 (LOX-1) in vascular endothelial cells. Circulation. 2005;112:II-1105. Presented at the American Heart Association 2005 Scientific Sessions, Dallas, TX, November 11-16, 2005.

26. Chang PY, Lu SC, Lee CM, Huang WH, Chen YJ, Liao WSL, Chen CH, Lee YT. Homocysteine impairs endothelial cell survival by repressing the transcriptional activity of the fibroblast growth factor 2 promoter. J Am Coll Cardiol. 2005. Presented at the 54th American College of Cardiology Scientific Sessions in Orlando, FL, March 6–9, 2005.

27. Lu J, Marcelli M, Liao WSL, Yang JH, Henry PD, Yang CY, Pownall HJ, Chen CH*. Dominant-negative Akt impairs endothelial cell survival by mimicking the inhibitory effect of electronegative LDL on FGF2 transcription. Circulation. 2004;110-III87. Presented at the American Heart Association 2004 Scientific Sessions, New Orleans, LA, November 7-10, 2004.

28. Chen CH*, Pace PW, Karakoc ND, Lu J, Chen HH, Henry PD, Pownall HJ, Foreyt JP, Ballantyne CM, Yang CY. Effective reduction of novel atherogenic LDL subfraction by atorvastatin in patients with hypercholesterolemia. J Am Coll Cardiol. 2004;43(suppl A):486A. Presented at the 53rd American College of Cardiology Scientific Sessions in New Orleans, LA, March 7–10, 2004.

29. Lu J, Chen HH, Suzuki S, Yang CY, Henry PD, Sawamura T, Chen CH*. Role of the LOX-1 receptor in transducing the apoptotic signals of circulating atherogenic LDL. J Am Coll Cardiol. 2004;43(suppl A):26A. Presented at the 53rd American College of Cardiology Scientific Sessions in New Orleans, LA, March 7–10, 2004.

30. Jiang W, Lu J, Yang JH, Chang PY, Lee YT, Marcelli M, Henry PD, Liao WSL, Chen CH*. Atherogenic LDL impairs vascular endothelial cell survival by disrupting the FGF2-PI3K-Akt autoregulatory loop. J Am Coll Cardiol. 2004;43(suppl A):499A. Presented at the 53rd American College of Cardiology Scientific Sessions in New Orleans, LA, March 7–10, 2004.

Chen, Chu-Huang

9

31. Lu J, Marathe GK, Yang CY, Jiang W, Yang JH, Pownall HJ, Henry PD, Chen CH*. Platelet-activating factor-like lipids mediate endothelial cell apoptosis induced by hypercholesterolemic LDL. J Am Coll Cardiol. 2003;41(Supple):243A. Presented at the 52nd American College of Cardiology Scientific Sessions in Chicago, IL, March 30–April 2, 2003.

32. Chen CH*, Jiang T, Yang JH, Jiang W, Pownall HJ, Ballantyne CM, Lu J, Henry PD, Yang CY. Induction of vascular endothelial cell apoptosis through the platelet-activating factor receptor in hypercholesterolemia. Atherosclerosis. 2002;3:88. Presented at the 73rd European Atherosclerosis Society Congress, Salzburg, Austria, July 7-10, 2002.

33. Lu J, Suzuki S, Safi HJ, Jiang W, Henry PD, Yang JH, Morrisett JD, Chen CH*. OxLDL LDL-induced vascular endothelial cell apoptosis involves ceramide-mediated Akt dephosphorylation: protective role of FGF2 overexpression. Atherosclerosis. 2002;3:88. Presented at the 73rd European Atherosclerosis Society Congress, Salzburg, Austria, July 7-10, 2002.

34. Jiang W, Lu J, Chang PY, Yang JH, Henry PD, Marcelli M, Chen CH*. Oxidized LDL induces endothelial cell apoptosis by impairing the FGF2-PI3K-Akt pathway. Circulation. 2002;105:e86-e119. Presented at the American Heart Association-Asia Pacific Scientific Forum, Honolulu, Hawaii, April 23-26, 2002.

35. Lu J, Suzuki S, Safi HJ, Jiang W, Henry PD, Yang CY, Chen CH*. FGF2 overexpression prevents ceramide-mediated Akt deactivation in endothelial cells exposed to oxidized LDL. Arterioscler Thromb Vasc Biol. 2002;22:878-a. Presented at the American Heart Association-3rd Annual ATVB council meeting, Salt Lake City, Utah, April 6-8, 2002.

36. Chen CH*, Yang JH, Morrisett JD, Lu J, Jiang T, Henry PD, Yang CY. Proapoptotic activity of a novel LDL subfraction in hypercholesterolemic human plasma. Circulation. 2001;104:II297. Presented at AHA 2001 Scientific Sessions 2001 of the American Heart Association, Anaheim, CA, November 11-14, 2001.

37. Chen CH*, Yang JH, Luo S, Chang PY, Gross R, Wu S, Henry PD. Oxidized LDL-induced endothelial cell apoptosis: role of mediator phospholipids and bFGF. Atherosclerosis. 2000;151:215. Presented at the XIIth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29, 2000.

C. Research Support Grants a) Ongoing Research Support 1. RO-1 U01 DK-57177 PI: Foreyt, John P. 09/01/200108/31/2014 National Institutes of Health/NIDDK Look Ahead: Study of Health Outcomes of Weight-Loss Role: Co-investigator

2. National Science Council, Taiwan PI: Chen, Chu-Huang 08/01/2011 to 07/31/2014 Potential link of L5 to coronary plaques in acute coronary syndrome The goal is to examine the how L5 contributes to the plaque formation and rupture in acute myocardial infarction in the Taiwanese population. Total Direct Cost: $185,000 (NTD550,000, for a duration of 3 years)

3. diaDexus, Inc. PI: Chen, Chu-Huang 03/01/2012 to 02/28/2013 The differential association of lipoprotein-associated phospholipase A2 and subfractions of LDL, VLDL, and HDL The goal is to determine the association of Lp-PLA2 and lipoprotein subfractions. b) Pending support 1. RO-1 PI: Chen, Chu-Huang 10/01/2013 to 9/30/2018 National Institutes of Health Electronegative LDL induces endothelial senescence by activating p53 signaling

Chen, Chu-Huang

10

2. Research Award PI: Chen, Chu-Huang 07/01/2013 to 06/30/2016 American Diabetes Association Electronegative LDL damages mitochondrial DNA through a p53 pathway in diabetes 3. Grant in Aid PI: Chen, Chu-Huang 07/01/2013 to 06/30/2015 American Heart Association Electronegative LDL damages vascular endothelium by perturbing p53 dynamics

c) Completed Research Support (recent) 1. MacDonald Research Fund PI: Chen, Chu-Huang 06/01/2010–06/30/2012 Roderick D. MacDonald Research Fund at St. Luke’s Episcopal Hospital Clinical correlation between L5 and ST elevation myocardial infarction: A pilot study The goal is to determine the pathogenic role of L5 in ST-elevation MI.

2. Independent Medical Research Grant PI: Chen, Chu-Huang 09/01/0806/30/11 Merck-Schering Plough Pharmaceuticals Effects of Ezetimibe and Vytorin on Reducing L5 in Patients with Metabolic Syndrome The goal is to examine the therapeutic effects of various drugs on L5 reduction

3. Training Grant T32 HL07812-0181 PI: Morrisett, Joel D. 07/01/199706/30/12 National Institutes of Health Training Grant in Atherosclerosis and Vascular Biology The major goals of this project are to equip a cadre of bright, young biomedical scientists with the skills that will enable them to conduct state-of-the-art basic and clinical research in the area of atherosclerosis/vascular biology. The ultimate goal is to train both predoctoral students and postdoctoral fellows to develop new, creative and effective approaches for the prevention and treatment of atherosclerosis. Role: Co-investigator

4. Research Award, #1-04-RA-13 PI: Chen, Chu-Huang 01/01/0412/31/06 American Diabetes Association Phospholipid-mediated vascular endothelial cell apoptosis in hyperlipidemia (in patients with diabetes) The major goal is to determine the mechanism of EC apoptosis induced by diabetic LDL.

5. Research Award PI: Chen, Chu-Huang 09/01/0512/31/09 Philip Morris Inc. Atherogenic mechanisms and potential treatments of a highly electronegative, mildly oxidized low-density lipoprotein subfraction circulating in smoking subjects The goal is to analyze atherogenic LDL subfractions in the plasma of smoking subjects and to examine whether these LDL subfractions can be eliminated or reduced pharmacologically.

6. Multi-center clinical trial PI: Foreyt, John P. 01/01/07–12/31/2008 Orexigen Therapeutics A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/ Bupropion Sustained Release (SR) and Placebo in Subjects with Obesity Participating in a Behavior Modification Program. Role: Co-investigator

7. Multi-center clinical trial PI: Foreyt, John P. 01/01/06–12/31/09 Sanofi-Aventis, US, Inc. Protocol No. EFC5107 – A Randomized, Double-Blind, Placebo-Controlled, Multicenter study to assess the efficacy and safety of long-term administration of rimonabant in the prevention of Type 2 Diabetes in Patients with prediabetic status.

Chen, Chu-Huang

11

Role: Co-investigator

8. Independent Medical Research Grant PI: Chen, Chu-Huang 01/01/0412/31/05 Pfizer Pharmaceuticals Role of electronegative LDL in left ventricular hypertrophy and acute coronary syndromes: Efficacy of atorvastatin in reducing LV mass and risk of sudden cardiac death The goal is to determine whether electronegative LDL is associated with increased LV mass and sudden cardiac death. D. Patents 1. Provisional Patent PI: Chu-Huang Chen 09/09/2011-09/08/2012 EFS ID: 10916381 Identification of specific apolipoprotein epitopes on circulating atherogenic low-density lipoprotein E. Invited Lectures (recent) 1. Biological significance of electronegative lipoproteins. School of Medicine, Tzu Chi University, Hualien,

Taiwan, May 3, 2013. 2. Chemical, molecular, and in vivo evidence of L5 as circulating atherogenic LDL. Center for Translational

Cancer Research, Institute of Biosciences and Technology (IBT), Texas A&M Health Science Center, Houston, Texas, March 11, 2013.

3. Electronegative LDL Increases Cardiac Arrhythmogenicity by Activating CaMKII and Suppressing ATP-Sensitive Potassium Channels. Asia Pacific Heart Rhythm Society 2012 (APHRS2012), Taipei, Taiwan, October 3-6, 2012.

4. Cardiovascular Implications of L5: A New Focus of Treatment. The Mount Sinai Hospital, New York, NY, July 19, 2012.

5. Cardiovascular Implications of L5: A New Focus of Treatment. New York Heart Research Foundation, New York, NY, July 17, 2012.

6. Surge of Electronegative LDL in Acute MI: A new focus of Treatment. Cardiovascular Basic Science Seminar of Texas Heart Institute, Baylor College of Medicine, and UT-Houston Medical School, in Houston, TX, October 27, 2011.

7. Identification of V5, the electronegative and atherogenic VLDL subfraction, in metabolic syndrome. Merck Pharmaceuticals Research Group, at the American Diabetes Association 71st Scientific Sessions in San Diego, CA, June 25, 2011.

8. L5 and Vascular Pathology, on Symposium: New Frontier in Diagnosis and Management of CV Disease in 2010, for 30th Anniversary of CMUH, China Medical University Hospital-Taiwan, Taichung, Taiwan, November 21, 2010. (Post-symposium invited publication: Asian J Health Sciences 2011 – see Publication)

9. Unique chemical characteristics of naturally occurring atherogenic LDL. 11th Eurasia Conference on Chemical Sciences (EuAsC2S-11), Dead Sea, Jordan, October 6–10, 2010. (Post-symposium invited publication: Pure Appl Chemistry 2011 – see Publication)

10. L5: A potential novel treatment target for diabetic vasculopathy. International Symposium on Integrative Approaches in the Battle Against Diabetes, Kangwon National University, Chunchon, Korea, September 9, 2010.

11. Potential Link between L5 and Stroke. Neurology and Neurosurgery combined Grand Round, China Medical University Hospital-Taiwan, Taichung, Taiwan, June 9, 2010.

12. L5—Our new direction. Kaohsiung Medical University Hospital Cardiovascular Science Symposium 2009, Kaohsiung, Taiwan, December 20, 2009.

13. When LDL becomes negatively charged. Graduate Institute of Biomedical Sciences, Chang Gung University, Seminar Series, Taipei, Taiwan, December 18, 2009.

14. When “bad cholesterol” takes a further negative spin. THI/UT/MDACC Cardiovascular Research Seminar Series, Houston, Texas, December 3, 2009.

Chen, Chu-Huang

12

15. Mechanism of L5 formation stimulated by chronic smoking. Philip Morris International Research Center at Leuven, Belgium, October 16, 2009.

16. Smoker L5 induced endothelial dysfunction. Philip Morris International Research Center at Cologne, Germany, October 15, 2009.

17. Cardiovascular Disease & Stroke Cardiovascular Conference: Mechanistic basis of L5 as a novel treatment target for coronary artery disease. Texas Tech University Health Sciences Center. Lubbock, Texas, August 20, 2009.

18. Topnotch Research Projects Strategic Conference: L5 as a causative factor for and marker of coronary artery disease. China Medical University Hospital, Taichung, Taiwan, July 15, 2009.

19. Targeted prevention of tobacco-associated atherosclerosis. Philip Morris International Special Lecture Invitation. Neuchatel, Switzerland, May 27, 2009.

20. Atherosclerosis and Vascular Biology Training Center Research Seminar Series, Baylor College of Medicine, Houston, Texas; October 9, 2008: L5—Functional properties and clinical implications

21. The 26th World Chinese Trader Convention, Special Lecture Series, New York, New York; September 14, 2008: Electronegative LDL—A new mechanism and treatment target for cardiovascular disease

22. Cardiovascular Basic Science Seminar, Baylor College of Medicine, Houston, Texas; September 9, 2008: Electronegative LDL—What is it, who has it, what does it do to you?

23. The 8th Annual Emerging Information and Technology Conference (EITC-2008), National Cheng Kung University, Tainan, Taiwan; June 26–27, 2008. Invited lecture: New mediators of smoking-incurred endothelial progenitor dysfunction

24. Institutional Grand Round, National Research Institute of Chinese Medicine, Taipei, Taiwan; June 24, 2008: Why is Smoking Bad for You? New Clues to an Old Enigma

25. Cardiology Section Grand Round, Chang-Gung Memorial Hospital, Taipei, Taiwan; June 23, 2008: Why is Smoking Bad for You? New Clues to an Old Enigma

26. Department of Medicine Grand Round, China Medical University, Taichung, Taiwan; June 20, 2008: Atherogenicity of Electronegative LDL—New Mechanism of Smoking-Incurred Endothelial Progenitor Dysfunction

27. American Heart Association, Western Review Consortium Study Group 4A Grant review meeting; Los Angele, California, April 15-16, 2008

28. 1st International Conference on Drug Design and Discovery, Dubai, UAE; February 4-7, 2008. Session Lecture: New drug development following characterization of a novel atherogenic lipoprotein

29. The Seventh Annual Emerging Information and Technology Conference (EITC-2007), Princeton University, New Jersey; June 9-10, 2007. Invited speech: The potential anticancer effects of electronegative LDL, a biological nanoparticle

30. Kaohsiung Medical University Hospital 50th Anniversary Cardiovascular Symposium, Kaohsiung, Taiwan; June 10, 2007, Keynote Speech: Structural characterization and signal mapping of electronegative LDL

31. American Heart Association, Western Review Consortium Study Group 4A Grant review meeting; Houston, Texas; April 18-19, 2007

32. 2006 World Congress of Internal Medicine, November 10-13, 2006, Taipei, Taiwan; Symposium: Hyperlipidemia and Cardiovascular Diseases: Clinical Challenge in IT Era; Invited Lecture: New Strategies of LDL Lowering: From Bench to Clinical Work

33. The Sixth Annual Emerging Information Technology Conference (EITC-2006), University of Texas at Dallas, Dallas, Texas; August 10-11, 2006. Invited speech: What is L5, a recently discovered biological nanoparticle, and how does it affect your health?

34. Department of Molecular and Cellular Oncology, UT-MD Anderson Cancer Center, Houston, Texas; May 31, 2006. Invited seminar: L5, a circulating lipoprotein that erodes your arteries

35. American Heart Association, Western Review Consortium Study Group 4A Grant review meeting; Salt Lake City, Utah,; April 18-19, 2006

Chen, Chu-Huang

13

36. Atorvastatin Research Award (ARA) Summit Meeting, February 10-12, 2006, Salt Lake City, Utah; Invited speech: Introductory Talk for the Summit: The ARA and My Career Development

F. Teaching 1. Graduate course – Cardiovascular Sciences, Baylor College of Medicine. 2. Attending physician – VA Hospital, a Baylor College of Medicine teaching hospital.